Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 2Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 49Carcinoma, Renal Cell 30Neoplasm Metastasis 18Neoplasms 15Kidney Neoplasms 14Neuroendocrine Tumors 11Carcinoma, Neuroendocrine 9Prostatic Neoplasms 7Melanoma 7Triple Negative Breast Neoplasms 6Thyroid Neoplasms 6Sarcoma 6Meningioma 6Lymphoma 6Glioma 6Endometrial Neoplasms 6Tuberous Sclerosis 5Stomach Neoplasms 5Recurrence 5Lymphoma, Mantle-Cell 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Liver Neoplasms 4Carcinoma, Islet Cell 4Astrocytoma 4

Interventions

Everolimus 2Sirolimus 1Sertraline 1Selective Serotonin Reuptake Inhibitors 1Medical Marijuana 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Autistic Disorder × Everolimus × Clear all
NCT01929642 2021-03-29

RAPT

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 2 Completed
3 enrolled 10 charts

Autistic Disorder, Tuberous Sclerosis, Self-Injurious Behavior

NCT01289912 2018-01-25

TSC

Boston Children's Hospital

Phase 2 Completed
52 enrolled 12 charts

Autistic Disorder, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡